Baxdrostat (Baxfendy) for Hypertension

Baxdrostat is a highly selective aldosterone synthase inhibitor FDA-approved for treating uncontrolled and resistant hypertension, providing clinically meaningful blood pressure reductions of approximately 8-10 mmHg systolic when added to existing antihypertensive regimens, though hyperkalemia monitoring is essential. 1

Indications

Baxdrostat is indicated for:

Uncontrolled hypertension: Patients with seated systolic BP ≥140 mmHg despite stable treatment with 2+ antihypertensive medications including a diuretic 2
Resistant hypertension: Patients with BP ≥140/90 mmHg despite optimal doses of 3+ antihypertensive medications including a diuretic 3

The 2024 ESC guidelines specifically mention baxdrostat as a newer agent being tested for treating primary aldosteronism and resistant hypertension, alongside non-steroidal MRAs 4. This represents an important addition to the treatment armamentarium, as resistant hypertension affects 8.5-20% of hypertensive adults and carries 50% higher cardiovascular risk 5.

Dosage and Administration

Starting dose: 1 mg orally once daily 1

Target dose: 2 mg orally once daily (can be increased after appropriate monitoring) 1

Timing: Take at the most convenient time of day to establish habitual medication-taking and improve adherence 4. Consistency in timing and setting is crucial 4.

Administration: Can be taken with or without food 1

Required Testing and Monitoring

Before Initiation:

Serum potassium level (must be <4.5 mmol/L for MRAs per guidelines) 6
eGFR assessment 1
Serum sodium 1

After Initiation:

Serum potassium monitoring is critical - check regularly, especially in first 12 weeks 1
Monitor for hyperkalemia (K+ >5.5 mmol/L occurs in ~20-30% of patients) 2, 3
Serum sodium monitoring 1
Blood pressure response assessment at monthly intervals until control achieved 7

Efficacy Data

The evidence for baxdrostat is remarkably strong and recent:

Seated systolic BP reduction:

Placebo-corrected reduction of -8.7 mmHg (1 mg dose) and -9.8 mmHg (2 mg dose) at 12 weeks 2
Meta-analysis confirms overall reduction of -6.25 to -8.93 mmHg 8, 9

24-hour ambulatory BP reduction:

Placebo-corrected reduction of -14.0 mmHg in resistant hypertension 3
Night-time systolic BP reduced by -13.19 mmHg 8

BP control rate: 74% higher likelihood of achieving BP <130 mmHg compared to placebo 8

Mechanism: Reduces serum aldosterone by approximately -3.49 ng/dL, directly targeting aldosterone dysregulation without affecting cortisol 8, 10

Adverse Effects

Common:

Hyperkalemia (most frequent):
- K+ >5.5 mmol/L: occurs in 20-30% of patients 2, 3
- K+ >6.0 mmol/L: occurs in 2-3% of patients 2
- Severe hyperkalemia (>6.5 mmol/L) is NOT significantly increased 11
Increased serum potassium by mean of 0.47 mmol/L 9
Overall adverse events: 24% more common than placebo 9

Serious:

No significant increase in serious adverse events compared to placebo 9, 10
No significant increase in hypotension, hyponatremia, or mortality 11
Discontinuation due to hyperkalemia comparable to control 11

Key Safety Point:

While potassium elevations >5.5 and >6.0 mmol/L serve as important safety signals requiring monitoring, the absence of significant severe hyperkalemia (>6.5 mmol/L) provides reassurance about the overall safety profile 11.

Contraindications

Based on FDA labeling and clinical trial exclusion criteria 1:

Pregnancy (as with all aldosterone antagonists) 1
Baseline serum potassium >4.5 mmol/L (relative contraindication based on MRA guidelines) 6
Severe renal impairment (eGFR <40 mL/min/1.73 m² - limited data) 3

Clinical Positioning

When to Use Baxdrostat:

4th-line agent for resistant hypertension when:

Patient on optimal 3-drug combination (ACEi/ARB + CCB + thiazide-like diuretic) 5, 12
Serum potassium <4.5 mmol/L 6
eGFR ≥45 mL/min/1.73 m² 5

Alternative to spironolactone when:

Spironolactone causes intolerable antiandrogenic effects (gynecomastia, erectile dysfunction) 4
Patient cannot tolerate steroidal MRAs 4
More selective aldosterone inhibition desired without cortisol effects 10

Advantages Over Spironolactone:

Highly selective - inhibits aldosterone synthase without affecting cortisol production 10
Once-daily dosing (vs. spironolactone's variable dosing) 1
No antiandrogenic effects (unlike spironolactone) 4
Linear dose-response: each 1 mg increase reduces systolic BP by 3.31 mmHg 8

Alternative Therapies

If baxdrostat is contraindicated or not tolerated 5, 12:

First alternative: Spironolactone 25-50 mg daily (if K+ <4.5 mmol/L and eGFR ≥45) - reduces BP by 6.6-8.7 mmHg 12

Second alternative: Eplerenone (more selective steroidal MRA, but less potent) 4

Other alternatives 5, 12:

Amiloride 10-20 mg (as effective as spironolactone)
Beta-blockers (if not already used)
Alpha-blockers (doxazosin)
Central sympatholytics (clonidine)
Direct vasodilators (hydralazine + beta-blocker + loop diuretic)
Aprocitentan (dual endothelin receptor antagonist) - reduces BP by 4-6 mmHg but causes edema in 9-18% 12

Device-based therapy: Renal denervation may be considered in carefully selected patients with systolic/diastolic hypertension, eGFR ≥40, and suitable anatomy, though effects are modest (3-5 mmHg reduction) 5

Critical Clinical Pearls

Hyperkalemia is expected but manageable: The 3-8 fold increased risk of hyperkalemia >5.5 mmol/L requires vigilant monitoring, but severe hyperkalemia (>6.5 mmol/L) is not significantly increased 11
Dose-dependent efficacy: 2 mg dose provides greater BP reduction and higher control rates than 1 mg 8
Works in CKD: Effective even in patients with eGFR 30-59 mL/min/1.73 m², though hyperkalemia risk is higher 13
Targets pathophysiology: Directly addresses aldosterone dysregulation, the key driver of resistant hypertension 10
Trial Sequential Analysis confirms conclusive evidence for BP reduction - the evidence base is robust 11

What are the dosage, indications, contraindications, monitoring requirements, adverse effects, and alternative therapies for baxfendy (baxdrostat) in hypertension?

Have a follow-up question?